Table 1.
Baseline Characteristics by Lymphovascular (LVI) Status
| Variable | LVI (n=74) | No LVI (n=92) | p-value* |
|---|---|---|---|
| Mean Age (SD), years | 52 (1.6) | 51 (1.1) | 0.72 |
| Race | |||
| Non-Hispanic White | 29 (39%) | 30 (33%) | 0.34 |
| Black | 10 (14%) | 24 (26%) | |
| Hispanic | 30 (41%) | 33 (36%) | |
| Other | 1 (1%) | 2 (2%) | |
| Unknown | 4 (5%) | 3 (3%) | |
| Type | |||
| Ductal Carcinoma | 60 (81%) | 77 (86%) | 0.33 |
| Lobular Carcinoma | 5 (7%) | 7 (8%) | |
| Other | 9 (12%) | 5 (6%) | |
| Size | |||
| 0-5cm | 55 (76%) | 74 (80%) | 0.53 |
| >5cm | 17 (24%) | 18 (20%) | |
| Grade | |||
| Low (I & II) | 25 (34%) | 29 (33%) | 0.911 |
| High (III) | 49 (66%) | 59 (67%) | |
| Subtype | |||
| Hormone Receptor+/HER2− | 37 (50%) | 35 (38%) | 0.29 |
| HER2 + | 22 (30%) | 36 (39%) | |
| Triple Negative | 15 (20%) | 21 (23%) | |
| Pathological Staging | |||
| pCR** | 0 (0%) | 34 (36%) | <0.001 |
| T+, N − | 9 (12%) | 29 (32%) | |
| Node + | 65 (88%) | 29 (32%) | |
| Surgery Type | |||
| Lumpectomy | 11 (15%) | 40 (44%) | <0.001 |
| Mastectomy | 63 (85%) | 51 (56%) | |
| Adjuvant Radiation | |||
| Yes | 70 (97%) | 74 (84%) | 0.006 |
| No | 2 (3%) | 14 (16%) | |
| Adjuvant Hormonal Therapy | |||
| Yes | 53 (75%) | 54 (68%) | 0.40 |
| No | 18 (25%) | 25 (32%) | |
| Neoadjuvant/Adjuvant Herceptin | |||
| Yes | 19 (27%) | 36 (52%) | 0.003 |
| No | 51 (73%) | 33 (48%) |
*
p-values represent t-tests for continuous and chi square or Fisher's exact tests for categorical variables.
**
pCR – pathological complete response